Download REFERENCES 1. Hindler JF, Stelling J. Analysis and presentation of

REFERENCES
1. Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus
guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2007;44:867-873.
2. Binkley S, Fishman NO, LaRosa LA, et al. Comparison of unit‐specific and hospital‐wide
antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control
Hosp Epidemiol. 2006; 27:682-687.
3. Dellit TH, Owens RC, McGowan JE, Jr, et al. Infectious Diseases Society of America and the Society
for Healthcare Epidemiology of America guidelines for developing an institutional program to
enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159.
4. Gerding DN. The search for good antimicrobial stewardship. Jt Comm J Qual Improv. 2001;27:403404.
5. Society for Healthcare Epidemiology of America. Primer on Healthcare Epidemiology, Infection
Control, and Antimicrobial Stewardship. SHEA.org Web site. Available at:
http://www.fellowscourse.shea-online.org/default.aspx. Published May 2015. Accessed on April 1,
2016.
6. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and
septic urinary tract infection—7 days or less versus longer treatment: systematic review and metaanalysis of randomized controlled trials. J Antimicrob Chemother. 2013;68:2183-2191.
7. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with
acute pyelonephritis: a randomized, open-label and double-blind, placebo-controlled, non-inferiority
trial. Lancet. 2012;380;484-490.
8. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750
mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of
complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71:17-22.
9. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of
skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect
Dis. 2014;59:147-159.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American
Thoracic Society consensus guidelines on the management of community-acquired pneumonia in
adults. Clin Infect Dis. 2007;44:s27-s72.
11. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the
management of adults with hospital-acquired, ventilator-associated, and healthcare-associated
pneumonia. Am J Respir Care Med. 2005;171:388-415.
12. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in
acute respiratory tract infections (review). Cochrane Database Syst Rev. 2012;9:CD007498.
13. Clinical Test Catalog: Procalcitonin. The University of Michigan Department of Pathology. The
University of Michigan Department of Pathology Web site. Available at:
https://www.pathology.med.umich.edu/handbook/#/details/4834. Accessed April 2016.
14. Høgli JU, Garcia BH, Skjold F, et al. An audit and feedback intervention study increased adherence
to antibiotic prescribing guidelines at a Norwegian hospital. BMC Infect Dis. 2016;16:96.
14. Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community
hospital’s antimicrobial stewardship program. Am J Infect Control. 2013;41:145-148.
15. Nowak MA, Nelson RE, Breidenbach JL, et al. Clinical and economic outcomes of a prospective
antimicrobial stewardship program. Am J Health Syst Pharm. 2012;69:1500-1508.
16. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use
among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp
Epidemiol. 2012;33:354-361.
17. Cardoso T, Ribeiro O, Aragão IC, et al. Additional risk factors for infection by multidrug-resistant
pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis. 2012;12:297.
18. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating healthcare associated infections and
deaths in US hospitals, 2002. Public Health Rep. 2007;122:160-166.
19. Yokoe DS, Anderson DJ, Berenholtz SM, et al. A compendium of strategies to prevent healthcareassociated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol.
2014;35:967.
20. Marchetti A, Rossiter R. Economic burden of healthcare-associate infection in US acute care
hospitals: societal perspective. J Med Econ. 2013;16:1399-1404.
21. National Action Plan to Prevent Health Care-Associated Infections: Road Map to Elimination – Part
1: Executive Summary, Metrics, and Goals. Health.gov Web site. Available at:
http://health.gov/hcq/pdfs/hai-action-plan-executive-summary.pdf. Published April 2013. Accessed
April 1, 2016.
22. Krein SL, Fowler KE, Ratz D, et al. Preventing device-associated infections in US hospitals: national
surveys from 2005 to 2013. BMJ Qual Saf. 2015;24:385-392.
23. Daniels KR, Lee GC, Frei CR. Trends in catheter-associated urinary tract infections among a
national cohort of hospitalized adults, 2001-2010. Am J Infect Control. 2014;42:17-22.
24. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheterassociated urinary tract infection in adults: 2009 international clinical practice guidelines from the
Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625-663.
25. Meddings J, Rogers MA, Krein SL, et al. Reducing unnecessary urinary catheter use and other
strategies to prevent catheter-associated urinary tract infection: an integrative review. BMJ Qual Saf.
2014;23:277-289.
26. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter-associated urinary tract infections
in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:464-479.
27. Palese A, Buchini S, Deroma L, et al. The effectiveness of the ultrasound bladder scanner in
reducing urinary tract infections: a meta-analysis. J Clin Nurs. 2010;19:2970-2979.
28. Gould CV, Umscheid CA, Agarwal RK. Guideline for prevention of catheter-associated urinary tract
infections 2009. Infect Control Hosp Epidemiol. 2010;31:319-326.
29. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1,
from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother.
2001;45:1151-1161.
30. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant
Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165-170.
31. Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenemresistant Enterobacteriaceae (CRE) – November 2015 Update CRE Toolkit. Available at:
http://www.cdc.gov/hai/organisms/cre/cre-toolkit/. Updated December 23, 2015. Accessed on April
1, 2016.
32. Akova M, Daikos GL, Tzouvelekis L, Carmel Y. Interventional strategies and current clinical
experience with carbapenemase-producing gram-negative bacteria. Clin Microbiol Infect. 2012; 18:
439-448.
33. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US
communities, 2012-2013. JAMA. 2015;314:1479-1487.
34. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae
infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol.
2008;29:1099-1106.
35. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenemresistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20:1170-1175.
36. Nabarro LE, Veeraraghavan B. Combination therapy for carbapenem-resistant
Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions. Eur J Clin
Microbiol Infect Dis. 2015;34:2307-2311.
37. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States,
2013. CDC.gov Web site. Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013508.pdf. Published 2013. Accessed April 2016.
38. Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and Infection by Klebsiella
pneumoniae carbapenemase–producing Enterobacteriaceae in long-term acute-care hospitals. Clin
Infect Dis. 2015;60:1153-1161.
39. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread
of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009;30:447-452.
40. Making Healthcare Safer: Stop Spread of Antibiotic Resistance. Center for Disease Control and
Prevention. CDC.gov Web site. Available at: http://www.cdc.gov/vitalsigns/stop-spread/index.html.
Updated August 4, 2015. Accessed on April 1, 2016.